Furthermore, dexamethasone, a clinical agent used in COVID-19 treatment, exerts partial inhibitory effects on IDO1 and AHR through glucocorticoid receptor-mediated pathways, contributing to reduced cytokine storm severity and enhanced viral clearance (Badawy, 2023). This evidence concerns the gene IDO1 and COVID-19.